Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients.
Arch Med Sci
; 18(4): 1100-1102, 2022.
Article
in English
| MEDLINE | ID: covidwho-1911941
ABSTRACT
Introduction:
Three-dose mRNA vaccination against COVID-19 is unable to elicit a sufficient immune response in immunocompromised subjects.Methods:
The aim of the study was to conduct a retrospective evaluation of the efficacy of a heterologous mRNA booster with mRNA-1273 in constantly seronegative kidney transplant recipients (KTRs) after three doses of the BNT162b2 mRNA vaccine. Twelve seronegative KTRs received a mRNA-1273 booster 5 months after the third dose of BNT162b2.Results:
A total of 5 out of 12 patients (41.7%) seroconverted, with a mean titer of 353 BAU/ml.Conclusions:
The administration of a heterologous mRNA vaccine as a booster may be an effective alternative for achieving post-vaccination immunity in seronegative KTRs.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
Topics:
Vaccines
Language:
English
Journal:
Arch Med Sci
Year:
2022
Document Type:
Article
Affiliation country:
Aoms
Similar
MEDLINE
...
LILACS
LIS